Global Mucopolysaccharidosis Therapeutics Market Research Report 2023
MPS, also known as mucopolysaccharidosis, refers to a group of key rare metabolic disorders which is caused by the absence, deficiency or malfunctioning of lysosomal enzymes called glycosaminoglycan (GAGs).
According to QYResearch’s new survey, global Mucopolysaccharidosis Therapeutics market is projected to reach US$ 3392.8 million in 2029, increasing from US$ 2381 million in 2022, with the CAGR of 5.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Mucopolysaccharidosis Therapeutics market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Mucopolysaccharidosis Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
According to QYResearch’s new survey, global Mucopolysaccharidosis Therapeutics market is projected to reach US$ 3392.8 million in 2029, increasing from US$ 2381 million in 2022, with the CAGR of 5.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Mucopolysaccharidosis Therapeutics market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Mucopolysaccharidosis Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
- Shire (Takeda Pharmaceutical Company Limited)
- Denali Therapeutics
- ArmaGen
- REGENXBIO Inc.
- Sangamo Therapeutics
- BioMarin
- Lysogene
- Abeona Therapeutics Inc.
- Ultragenyx Pharmaceutical
- Genzyme Corporation
- Intravenous
- Intracerebroventricular (ICV)
- Hospital
- Clinic
- Other
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Mucopolysaccharidosis Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Intravenous
1.2.3 Intracerebroventricular (ICV)
1.3 Market by Application
1.3.1 Global Mucopolysaccharidosis Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Mucopolysaccharidosis Therapeutics Market Perspective (2018-2029)
2.2 Mucopolysaccharidosis Therapeutics Growth Trends by Region
2.2.1 Global Mucopolysaccharidosis Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Mucopolysaccharidosis Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Mucopolysaccharidosis Therapeutics Forecasted Market Size by Region (2024-2029)
2.3 Mucopolysaccharidosis Therapeutics Market Dynamics
2.3.1 Mucopolysaccharidosis Therapeutics Industry Trends
2.3.2 Mucopolysaccharidosis Therapeutics Market Drivers
2.3.3 Mucopolysaccharidosis Therapeutics Market Challenges
2.3.4 Mucopolysaccharidosis Therapeutics Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Mucopolysaccharidosis Therapeutics Players by Revenue
3.1.1 Global Top Mucopolysaccharidosis Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Mucopolysaccharidosis Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Mucopolysaccharidosis Therapeutics Revenue
3.4 Global Mucopolysaccharidosis Therapeutics Market Concentration Ratio
3.4.1 Global Mucopolysaccharidosis Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Mucopolysaccharidosis Therapeutics Revenue in 2022
3.5 Mucopolysaccharidosis Therapeutics Key Players Head office and Area Served
3.6 Key Players Mucopolysaccharidosis Therapeutics Product Solution and Service
3.7 Date of Enter into Mucopolysaccharidosis Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 MUCOPOLYSACCHARIDOSIS THERAPEUTICS BREAKDOWN DATA BY TYPE
4.1 Global Mucopolysaccharidosis Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Mucopolysaccharidosis Therapeutics Forecasted Market Size by Type (2024-2029)
5 MUCOPOLYSACCHARIDOSIS THERAPEUTICS BREAKDOWN DATA BY APPLICATION
5.1 Global Mucopolysaccharidosis Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Mucopolysaccharidosis Therapeutics Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Mucopolysaccharidosis Therapeutics Market Size (2018-2029)
6.2 North America Mucopolysaccharidosis Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2023)
6.4 North America Mucopolysaccharidosis Therapeutics Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Mucopolysaccharidosis Therapeutics Market Size (2018-2029)
7.2 Europe Mucopolysaccharidosis Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2023)
7.4 Europe Mucopolysaccharidosis Therapeutics Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size (2018-2029)
8.2 Asia-Pacific Mucopolysaccharidosis Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Mucopolysaccharidosis Therapeutics Market Size (2018-2029)
9.2 Latin America Mucopolysaccharidosis Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2023)
9.4 Latin America Mucopolysaccharidosis Therapeutics Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size (2018-2029)
10.2 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Shire (Takeda Pharmaceutical Company Limited)
11.1.1 Shire (Takeda Pharmaceutical Company Limited) Company Detail
11.1.2 Shire (Takeda Pharmaceutical Company Limited) Business Overview
11.1.3 Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Introduction
11.1.4 Shire (Takeda Pharmaceutical Company Limited) Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023)
11.1.5 Shire (Takeda Pharmaceutical Company Limited) Recent Development
11.2 Denali Therapeutics
11.2.1 Denali Therapeutics Company Detail
11.2.2 Denali Therapeutics Business Overview
11.2.3 Denali Therapeutics Mucopolysaccharidosis Therapeutics Introduction
11.2.4 Denali Therapeutics Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023)
11.2.5 Denali Therapeutics Recent Development
11.3 ArmaGen
11.3.1 ArmaGen Company Detail
11.3.2 ArmaGen Business Overview
11.3.3 ArmaGen Mucopolysaccharidosis Therapeutics Introduction
11.3.4 ArmaGen Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023)
11.3.5 ArmaGen Recent Development
11.4 REGENXBIO Inc.
11.4.1 REGENXBIO Inc. Company Detail
11.4.2 REGENXBIO Inc. Business Overview
11.4.3 REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Introduction
11.4.4 REGENXBIO Inc. Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023)
11.4.5 REGENXBIO Inc. Recent Development
11.5 Sangamo Therapeutics
11.5.1 Sangamo Therapeutics Company Detail
11.5.2 Sangamo Therapeutics Business Overview
11.5.3 Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Introduction
11.5.4 Sangamo Therapeutics Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023)
11.5.5 Sangamo Therapeutics Recent Development
11.6 BioMarin
11.6.1 BioMarin Company Detail
11.6.2 BioMarin Business Overview
11.6.3 BioMarin Mucopolysaccharidosis Therapeutics Introduction
11.6.4 BioMarin Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023)
11.6.5 BioMarin Recent Development
11.7 Lysogene
11.7.1 Lysogene Company Detail
11.7.2 Lysogene Business Overview
11.7.3 Lysogene Mucopolysaccharidosis Therapeutics Introduction
11.7.4 Lysogene Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023)
11.7.5 Lysogene Recent Development
11.8 Abeona Therapeutics Inc.
11.8.1 Abeona Therapeutics Inc. Company Detail
11.8.2 Abeona Therapeutics Inc. Business Overview
11.8.3 Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Introduction
11.8.4 Abeona Therapeutics Inc. Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023)
11.8.5 Abeona Therapeutics Inc. Recent Development
11.9 Ultragenyx Pharmaceutical
11.9.1 Ultragenyx Pharmaceutical Company Detail
11.9.2 Ultragenyx Pharmaceutical Business Overview
11.9.3 Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Introduction
11.9.4 Ultragenyx Pharmaceutical Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023)
11.9.5 Ultragenyx Pharmaceutical Recent Development
11.10 Genzyme Corporation
11.10.1 Genzyme Corporation Company Detail
11.10.2 Genzyme Corporation Business Overview
11.10.3 Genzyme Corporation Mucopolysaccharidosis Therapeutics Introduction
11.10.4 Genzyme Corporation Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023)
11.10.5 Genzyme Corporation Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Mucopolysaccharidosis Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Intravenous
1.2.3 Intracerebroventricular (ICV)
1.3 Market by Application
1.3.1 Global Mucopolysaccharidosis Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Mucopolysaccharidosis Therapeutics Market Perspective (2018-2029)
2.2 Mucopolysaccharidosis Therapeutics Growth Trends by Region
2.2.1 Global Mucopolysaccharidosis Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Mucopolysaccharidosis Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Mucopolysaccharidosis Therapeutics Forecasted Market Size by Region (2024-2029)
2.3 Mucopolysaccharidosis Therapeutics Market Dynamics
2.3.1 Mucopolysaccharidosis Therapeutics Industry Trends
2.3.2 Mucopolysaccharidosis Therapeutics Market Drivers
2.3.3 Mucopolysaccharidosis Therapeutics Market Challenges
2.3.4 Mucopolysaccharidosis Therapeutics Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Mucopolysaccharidosis Therapeutics Players by Revenue
3.1.1 Global Top Mucopolysaccharidosis Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Mucopolysaccharidosis Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Mucopolysaccharidosis Therapeutics Revenue
3.4 Global Mucopolysaccharidosis Therapeutics Market Concentration Ratio
3.4.1 Global Mucopolysaccharidosis Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Mucopolysaccharidosis Therapeutics Revenue in 2022
3.5 Mucopolysaccharidosis Therapeutics Key Players Head office and Area Served
3.6 Key Players Mucopolysaccharidosis Therapeutics Product Solution and Service
3.7 Date of Enter into Mucopolysaccharidosis Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 MUCOPOLYSACCHARIDOSIS THERAPEUTICS BREAKDOWN DATA BY TYPE
4.1 Global Mucopolysaccharidosis Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Mucopolysaccharidosis Therapeutics Forecasted Market Size by Type (2024-2029)
5 MUCOPOLYSACCHARIDOSIS THERAPEUTICS BREAKDOWN DATA BY APPLICATION
5.1 Global Mucopolysaccharidosis Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Mucopolysaccharidosis Therapeutics Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Mucopolysaccharidosis Therapeutics Market Size (2018-2029)
6.2 North America Mucopolysaccharidosis Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2023)
6.4 North America Mucopolysaccharidosis Therapeutics Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Mucopolysaccharidosis Therapeutics Market Size (2018-2029)
7.2 Europe Mucopolysaccharidosis Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2023)
7.4 Europe Mucopolysaccharidosis Therapeutics Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size (2018-2029)
8.2 Asia-Pacific Mucopolysaccharidosis Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Mucopolysaccharidosis Therapeutics Market Size (2018-2029)
9.2 Latin America Mucopolysaccharidosis Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2023)
9.4 Latin America Mucopolysaccharidosis Therapeutics Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size (2018-2029)
10.2 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Shire (Takeda Pharmaceutical Company Limited)
11.1.1 Shire (Takeda Pharmaceutical Company Limited) Company Detail
11.1.2 Shire (Takeda Pharmaceutical Company Limited) Business Overview
11.1.3 Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Introduction
11.1.4 Shire (Takeda Pharmaceutical Company Limited) Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023)
11.1.5 Shire (Takeda Pharmaceutical Company Limited) Recent Development
11.2 Denali Therapeutics
11.2.1 Denali Therapeutics Company Detail
11.2.2 Denali Therapeutics Business Overview
11.2.3 Denali Therapeutics Mucopolysaccharidosis Therapeutics Introduction
11.2.4 Denali Therapeutics Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023)
11.2.5 Denali Therapeutics Recent Development
11.3 ArmaGen
11.3.1 ArmaGen Company Detail
11.3.2 ArmaGen Business Overview
11.3.3 ArmaGen Mucopolysaccharidosis Therapeutics Introduction
11.3.4 ArmaGen Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023)
11.3.5 ArmaGen Recent Development
11.4 REGENXBIO Inc.
11.4.1 REGENXBIO Inc. Company Detail
11.4.2 REGENXBIO Inc. Business Overview
11.4.3 REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Introduction
11.4.4 REGENXBIO Inc. Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023)
11.4.5 REGENXBIO Inc. Recent Development
11.5 Sangamo Therapeutics
11.5.1 Sangamo Therapeutics Company Detail
11.5.2 Sangamo Therapeutics Business Overview
11.5.3 Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Introduction
11.5.4 Sangamo Therapeutics Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023)
11.5.5 Sangamo Therapeutics Recent Development
11.6 BioMarin
11.6.1 BioMarin Company Detail
11.6.2 BioMarin Business Overview
11.6.3 BioMarin Mucopolysaccharidosis Therapeutics Introduction
11.6.4 BioMarin Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023)
11.6.5 BioMarin Recent Development
11.7 Lysogene
11.7.1 Lysogene Company Detail
11.7.2 Lysogene Business Overview
11.7.3 Lysogene Mucopolysaccharidosis Therapeutics Introduction
11.7.4 Lysogene Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023)
11.7.5 Lysogene Recent Development
11.8 Abeona Therapeutics Inc.
11.8.1 Abeona Therapeutics Inc. Company Detail
11.8.2 Abeona Therapeutics Inc. Business Overview
11.8.3 Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Introduction
11.8.4 Abeona Therapeutics Inc. Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023)
11.8.5 Abeona Therapeutics Inc. Recent Development
11.9 Ultragenyx Pharmaceutical
11.9.1 Ultragenyx Pharmaceutical Company Detail
11.9.2 Ultragenyx Pharmaceutical Business Overview
11.9.3 Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Introduction
11.9.4 Ultragenyx Pharmaceutical Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023)
11.9.5 Ultragenyx Pharmaceutical Recent Development
11.10 Genzyme Corporation
11.10.1 Genzyme Corporation Company Detail
11.10.2 Genzyme Corporation Business Overview
11.10.3 Genzyme Corporation Mucopolysaccharidosis Therapeutics Introduction
11.10.4 Genzyme Corporation Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023)
11.10.5 Genzyme Corporation Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global Mucopolysaccharidosis Therapeutics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Intravenous
Table 3. Key Players of Intracerebroventricular (ICV)
Table 4. Global Mucopolysaccharidosis Therapeutics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 5. Global Mucopolysaccharidosis Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Mucopolysaccharidosis Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Mucopolysaccharidosis Therapeutics Market Share by Region (2018-2023)
Table 8. Global Mucopolysaccharidosis Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Mucopolysaccharidosis Therapeutics Market Share by Region (2024-2029)
Table 10. Mucopolysaccharidosis Therapeutics Market Trends
Table 11. Mucopolysaccharidosis Therapeutics Market Drivers
Table 12. Mucopolysaccharidosis Therapeutics Market Challenges
Table 13. Mucopolysaccharidosis Therapeutics Market Restraints
Table 14. Global Mucopolysaccharidosis Therapeutics Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Mucopolysaccharidosis Therapeutics Market Share by Players (2018-2023)
Table 16. Global Top Mucopolysaccharidosis Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mucopolysaccharidosis Therapeutics as of 2022)
Table 17. Ranking of Global Top Mucopolysaccharidosis Therapeutics Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Mucopolysaccharidosis Therapeutics Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Mucopolysaccharidosis Therapeutics Product Solution and Service
Table 21. Date of Enter into Mucopolysaccharidosis Therapeutics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Mucopolysaccharidosis Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Type (2018-2023)
Table 25. Global Mucopolysaccharidosis Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Type (2024-2029)
Table 27. Global Mucopolysaccharidosis Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Application (2018-2023)
Table 29. Global Mucopolysaccharidosis Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Application (2024-2029)
Table 31. North America Mucopolysaccharidosis Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 32. North America Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Mucopolysaccharidosis Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 34. Europe Mucopolysaccharidosis Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. Europe Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Mucopolysaccharidosis Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 37. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Region (2024-2029) & (US$ Million)
Table 40. Latin America Mucopolysaccharidosis Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 41. Latin America Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Mucopolysaccharidosis Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 43. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 46. Shire (Takeda Pharmaceutical Company Limited) Company Detail
Table 47. Shire (Takeda Pharmaceutical Company Limited) Business Overview
Table 48. Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Product
Table 49. Shire (Takeda Pharmaceutical Company Limited) Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023) & (US$ Million)
Table 50. Shire (Takeda Pharmaceutical Company Limited) Recent Development
Table 51. Denali Therapeutics Company Detail
Table 52. Denali Therapeutics Business Overview
Table 53. Denali Therapeutics Mucopolysaccharidosis Therapeutics Product
Table 54. Denali Therapeutics Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023) & (US$ Million)
Table 55. Denali Therapeutics Recent Development
Table 56. ArmaGen Company Detail
Table 57. ArmaGen Business Overview
Table 58. ArmaGen Mucopolysaccharidosis Therapeutics Product
Table 59. ArmaGen Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023) & (US$ Million)
Table 60. ArmaGen Recent Development
Table 61. REGENXBIO Inc. Company Detail
Table 62. REGENXBIO Inc. Business Overview
Table 63. REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Product
Table 64. REGENXBIO Inc. Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023) & (US$ Million)
Table 65. REGENXBIO Inc. Recent Development
Table 66. Sangamo Therapeutics Company Detail
Table 67. Sangamo Therapeutics Business Overview
Table 68. Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Product
Table 69. Sangamo Therapeutics Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023) & (US$ Million)
Table 70. Sangamo Therapeutics Recent Development
Table 71. BioMarin Company Detail
Table 72. BioMarin Business Overview
Table 73. BioMarin Mucopolysaccharidosis Therapeutics Product
Table 74. BioMarin Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023) & (US$ Million)
Table 75. BioMarin Recent Development
Table 76. Lysogene Company Detail
Table 77. Lysogene Business Overview
Table 78. Lysogene Mucopolysaccharidosis Therapeutics Product
Table 79. Lysogene Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023) & (US$ Million)
Table 80. Lysogene Recent Development
Table 81. Abeona Therapeutics Inc. Company Detail
Table 82. Abeona Therapeutics Inc. Business Overview
Table 83. Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Product
Table 84. Abeona Therapeutics Inc. Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023) & (US$ Million)
Table 85. Abeona Therapeutics Inc. Recent Development
Table 86. Ultragenyx Pharmaceutical Company Detail
Table 87. Ultragenyx Pharmaceutical Business Overview
Table 88. Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Product
Table 89. Ultragenyx Pharmaceutical Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023) & (US$ Million)
Table 90. Ultragenyx Pharmaceutical Recent Development
Table 91. Genzyme Corporation Company Detail
Table 92. Genzyme Corporation Business Overview
Table 93. Genzyme Corporation Mucopolysaccharidosis Therapeutics Product
Table 94. Genzyme Corporation Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023) & (US$ Million)
Table 95. Genzyme Corporation Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
Table 1. Global Mucopolysaccharidosis Therapeutics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Intravenous
Table 3. Key Players of Intracerebroventricular (ICV)
Table 4. Global Mucopolysaccharidosis Therapeutics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 5. Global Mucopolysaccharidosis Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Mucopolysaccharidosis Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Mucopolysaccharidosis Therapeutics Market Share by Region (2018-2023)
Table 8. Global Mucopolysaccharidosis Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Mucopolysaccharidosis Therapeutics Market Share by Region (2024-2029)
Table 10. Mucopolysaccharidosis Therapeutics Market Trends
Table 11. Mucopolysaccharidosis Therapeutics Market Drivers
Table 12. Mucopolysaccharidosis Therapeutics Market Challenges
Table 13. Mucopolysaccharidosis Therapeutics Market Restraints
Table 14. Global Mucopolysaccharidosis Therapeutics Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Mucopolysaccharidosis Therapeutics Market Share by Players (2018-2023)
Table 16. Global Top Mucopolysaccharidosis Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mucopolysaccharidosis Therapeutics as of 2022)
Table 17. Ranking of Global Top Mucopolysaccharidosis Therapeutics Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Mucopolysaccharidosis Therapeutics Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Mucopolysaccharidosis Therapeutics Product Solution and Service
Table 21. Date of Enter into Mucopolysaccharidosis Therapeutics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Mucopolysaccharidosis Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Type (2018-2023)
Table 25. Global Mucopolysaccharidosis Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Type (2024-2029)
Table 27. Global Mucopolysaccharidosis Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Application (2018-2023)
Table 29. Global Mucopolysaccharidosis Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Application (2024-2029)
Table 31. North America Mucopolysaccharidosis Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 32. North America Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Mucopolysaccharidosis Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 34. Europe Mucopolysaccharidosis Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. Europe Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Mucopolysaccharidosis Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 37. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Region (2024-2029) & (US$ Million)
Table 40. Latin America Mucopolysaccharidosis Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 41. Latin America Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Mucopolysaccharidosis Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 43. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 46. Shire (Takeda Pharmaceutical Company Limited) Company Detail
Table 47. Shire (Takeda Pharmaceutical Company Limited) Business Overview
Table 48. Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Product
Table 49. Shire (Takeda Pharmaceutical Company Limited) Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023) & (US$ Million)
Table 50. Shire (Takeda Pharmaceutical Company Limited) Recent Development
Table 51. Denali Therapeutics Company Detail
Table 52. Denali Therapeutics Business Overview
Table 53. Denali Therapeutics Mucopolysaccharidosis Therapeutics Product
Table 54. Denali Therapeutics Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023) & (US$ Million)
Table 55. Denali Therapeutics Recent Development
Table 56. ArmaGen Company Detail
Table 57. ArmaGen Business Overview
Table 58. ArmaGen Mucopolysaccharidosis Therapeutics Product
Table 59. ArmaGen Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023) & (US$ Million)
Table 60. ArmaGen Recent Development
Table 61. REGENXBIO Inc. Company Detail
Table 62. REGENXBIO Inc. Business Overview
Table 63. REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Product
Table 64. REGENXBIO Inc. Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023) & (US$ Million)
Table 65. REGENXBIO Inc. Recent Development
Table 66. Sangamo Therapeutics Company Detail
Table 67. Sangamo Therapeutics Business Overview
Table 68. Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Product
Table 69. Sangamo Therapeutics Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023) & (US$ Million)
Table 70. Sangamo Therapeutics Recent Development
Table 71. BioMarin Company Detail
Table 72. BioMarin Business Overview
Table 73. BioMarin Mucopolysaccharidosis Therapeutics Product
Table 74. BioMarin Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023) & (US$ Million)
Table 75. BioMarin Recent Development
Table 76. Lysogene Company Detail
Table 77. Lysogene Business Overview
Table 78. Lysogene Mucopolysaccharidosis Therapeutics Product
Table 79. Lysogene Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023) & (US$ Million)
Table 80. Lysogene Recent Development
Table 81. Abeona Therapeutics Inc. Company Detail
Table 82. Abeona Therapeutics Inc. Business Overview
Table 83. Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Product
Table 84. Abeona Therapeutics Inc. Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023) & (US$ Million)
Table 85. Abeona Therapeutics Inc. Recent Development
Table 86. Ultragenyx Pharmaceutical Company Detail
Table 87. Ultragenyx Pharmaceutical Business Overview
Table 88. Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Product
Table 89. Ultragenyx Pharmaceutical Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023) & (US$ Million)
Table 90. Ultragenyx Pharmaceutical Recent Development
Table 91. Genzyme Corporation Company Detail
Table 92. Genzyme Corporation Business Overview
Table 93. Genzyme Corporation Mucopolysaccharidosis Therapeutics Product
Table 94. Genzyme Corporation Revenue in Mucopolysaccharidosis Therapeutics Business (2018-2023) & (US$ Million)
Table 95. Genzyme Corporation Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Mucopolysaccharidosis Therapeutics Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Mucopolysaccharidosis Therapeutics Market Share by Type: 2022 VS 2029
Figure 3. Intravenous Features
Figure 4. Intracerebroventricular (ICV) Features
Figure 5. Global Mucopolysaccharidosis Therapeutics Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 6. Global Mucopolysaccharidosis Therapeutics Market Share by Application: 2022 VS 2029
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Other Case Studies
Figure 10. Mucopolysaccharidosis Therapeutics Report Years Considered
Figure 11. Global Mucopolysaccharidosis Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 12. Global Mucopolysaccharidosis Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Mucopolysaccharidosis Therapeutics Market Share by Region: 2022 VS 2029
Figure 14. Global Mucopolysaccharidosis Therapeutics Market Share by Players in 2022
Figure 15. Global Top Mucopolysaccharidosis Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mucopolysaccharidosis Therapeutics as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Mucopolysaccharidosis Therapeutics Revenue in 2022
Figure 17. North America Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 18. North America Mucopolysaccharidosis Therapeutics Market Share by Country (2018-2029)
Figure 19. United States Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. Canada Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Europe Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Mucopolysaccharidosis Therapeutics Market Share by Country (2018-2029)
Figure 23. Germany Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. France Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. U.K. Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Italy Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Russia Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Nordic Countries Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Share by Region (2018-2029)
Figure 31. China Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Japan Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. South Korea Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Southeast Asia Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. India Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Australia Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Latin America Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Mucopolysaccharidosis Therapeutics Market Share by Country (2018-2029)
Figure 39. Mexico Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Brazil Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Share by Country (2018-2029)
Figure 43. Turkey Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Saudi Arabia Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Shire (Takeda Pharmaceutical Company Limited) Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2018-2023)
Figure 46. Denali Therapeutics Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2018-2023)
Figure 47. ArmaGen Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2018-2023)
Figure 48. REGENXBIO Inc. Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2018-2023)
Figure 49. Sangamo Therapeutics Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2018-2023)
Figure 50. BioMarin Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2018-2023)
Figure 51. Lysogene Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2018-2023)
Figure 52. Abeona Therapeutics Inc. Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2018-2023)
Figure 53. Ultragenyx Pharmaceutical Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2018-2023)
Figure 54. Genzyme Corporation Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2018-2023)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
Figure 1. Global Mucopolysaccharidosis Therapeutics Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Mucopolysaccharidosis Therapeutics Market Share by Type: 2022 VS 2029
Figure 3. Intravenous Features
Figure 4. Intracerebroventricular (ICV) Features
Figure 5. Global Mucopolysaccharidosis Therapeutics Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 6. Global Mucopolysaccharidosis Therapeutics Market Share by Application: 2022 VS 2029
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Other Case Studies
Figure 10. Mucopolysaccharidosis Therapeutics Report Years Considered
Figure 11. Global Mucopolysaccharidosis Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 12. Global Mucopolysaccharidosis Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Mucopolysaccharidosis Therapeutics Market Share by Region: 2022 VS 2029
Figure 14. Global Mucopolysaccharidosis Therapeutics Market Share by Players in 2022
Figure 15. Global Top Mucopolysaccharidosis Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mucopolysaccharidosis Therapeutics as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Mucopolysaccharidosis Therapeutics Revenue in 2022
Figure 17. North America Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 18. North America Mucopolysaccharidosis Therapeutics Market Share by Country (2018-2029)
Figure 19. United States Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. Canada Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Europe Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Mucopolysaccharidosis Therapeutics Market Share by Country (2018-2029)
Figure 23. Germany Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. France Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. U.K. Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Italy Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Russia Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Nordic Countries Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Share by Region (2018-2029)
Figure 31. China Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Japan Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. South Korea Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Southeast Asia Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. India Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Australia Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Latin America Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Mucopolysaccharidosis Therapeutics Market Share by Country (2018-2029)
Figure 39. Mexico Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Brazil Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Share by Country (2018-2029)
Figure 43. Turkey Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Saudi Arabia Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Shire (Takeda Pharmaceutical Company Limited) Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2018-2023)
Figure 46. Denali Therapeutics Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2018-2023)
Figure 47. ArmaGen Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2018-2023)
Figure 48. REGENXBIO Inc. Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2018-2023)
Figure 49. Sangamo Therapeutics Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2018-2023)
Figure 50. BioMarin Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2018-2023)
Figure 51. Lysogene Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2018-2023)
Figure 52. Abeona Therapeutics Inc. Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2018-2023)
Figure 53. Ultragenyx Pharmaceutical Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2018-2023)
Figure 54. Genzyme Corporation Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2018-2023)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
